Send to

Choose Destination
See comment in PubMed Commons below
Vaccine. 2002 May 22;20(17-18):2325-35.

Use of a rationally attenuated Bordetella bronchiseptica as a live mucosal vaccine and vector for heterologous antigens.

Author information

Molecular Bacteriology Group, Department of Veterinary Pathology, Glasgow University Veterinary School, Bearsden Road, Glasgow, UK.


Inactivation of the aroA gene of Bordetella bronchiseptica severely impaired its ability to colonise the respiratory tract of mice. The B. bronchiseptica aroA mutant was investigated as a live vaccine and vector for heterologous antigens. The B. bronchiseptica aroA mutant expressing the non-toxic fragment C (FrgC) of tetanus toxin (strain GVB120) was used to immunise mice intranasally. Immunised mice produced a strong serum and mucosal antibody response to B. bronchiseptica and serum anti-FrgC antibodies. Upon challenge with wild type B. bronchiseptica, immunised mice rapidly reduced the numbers of B. bronchiseptica in their respiratory tract, although clearance was more pronounced in the lower than in the upper respiratory tract. Immunisation with GVB120 protected approximately 40% of mice from tetanus toxin challenge. As far as we are aware, this is the first description of a recombinant B. bronchiseptica strain being used as a live vaccine vector for heterologous antigens.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center